Exenatide: Type 2 diabetes: For some overweight patients

Prescrire International

Volumn 16, Issue 92, 2007, Pages 228-231

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN DERIVATIVE; ANTIBIOTIC AGENT; BIGUANIDE DERIVATIVE; BUFORMIN; CARBUTAMIDE; CONTRACEPTIVE AGENT; EXENDIN 4; GLIBENCLAMIDE; GLIBORNURIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VILDAGLIPTIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; INCRETIN; PEPTIDE; VENOM;

ADJUVANT THERAPY; AGITATION; ARTICLE; BIRTH DEFECT; CLINICAL TRIAL; DIABETES CONTROL; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG MECHANISM; DRUG OVERDOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; MONOTHERAPY; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SIDE EFFECT; TERATOGENICITY; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INJECTIONS, SUBCUTANEOUS; METFORMIN; OVERWEIGHT; PEPTIDES; SULFONYLUREA COMPOUNDS; VENOMS; WEIGHT GAIN; WEIGHT LOSS;

EID: 36749059085     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Prescrire Editorial Staff "Treatment of type 2 diabetes" Prescrire Int 2002; 11 (63): 28-30.
2. Prescrire Editorial Staff "Pioglitazone, rosiglitazone, rosiglitazone + metformin" Prescrire Int 2005; 14 (78): 133-139.
3. Prescrire Editorial Staff "Insulin in type 2 diabetes" Prescrire Int 2005; 14 (79): 187-193.
4. Prescrire Editorial Staff "Weight gain with insulin and oral antidiabetics" Prescrire Int 2005; 14 (79): 191.
5. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-773. Medical review" 22 April 2005: 154 pages.
6. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-773. Statistical review" 8 December 2004: 19 pages.
7. Bus JB et al. "Effects of exenatide (extendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes" Diabetes Care 2004; 27 (11): 2628-2635.
8. Defronzo RA et al. "Effects of exenatide (extendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes" Diabetes Care 2005; 28 (5): 1092-1100.
9. Kendall DM et al. "Effects of exenatide (extendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea" Diabetes Care 2005; 28 (5): 1083-1091.
10. Heine RJ et al. "Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes" Ann Intern Med 2005; 143 (8): 559-569.
11. Barnett A et al. "A comparison of exenatide and insulin glargine in patients using a single oral antidiabetic agent" 42nd annual meeting of the European Association of the Study of Diabetes 16 September 2006: abstr. 0782 (1 page).
12. Nauck MA et al. "Effects of exenatide compared with twice-daily triphasic insulin aspart in patients with type 2 diabetes using metformin and a sulphonylurea" 42nd annual meeting of the European Association of the Study of Diabetes, 14 September 2006: abstr. 001 (1 page).
13. "Byetta. U.S. Summary of product characteristic" April 2006: 16 pages.
14. European Medicines Agency - CHMP "European Public Assessment Report (first version). Byetta - Scientific discussion: 27 pages; posted on the EMEA website on 20/11/2006.
15. Commission of the European Communities "Byetta°. Summary of Product Characteristics" 20 November 2006. Website ec.europa.eu accessed 7 June 2007: 13 pages.
16. Linnebjerg H et al. "Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes" Diabet Med 2006; 23 (3): 240-245.